Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Titel:
Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Perez, Edith A Awada, Ahmad O'Shaughnessy, Joyce Rugo, Hope S Twelves, Chris Im, Seock-Ah Gómez-Pardo, Patricia Schwartzberg, Lee S Diéras, Veronique Yardley, Denise A Potter, David A Mailliez, Audrey Moreno-Aspitia, Alvaro Ahn, Jin-Seok Zhao, Carol Hoch, Ute Tagliaferri, Mary Hannah, Alison L Cortes, Javier